Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen
The breakthrough therapy designation is based on data from the company’s ongoing Phase III clinical trial program that is evaluating the all-oral combination regimen of DCV, an investigational
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.